Duplex/colour Doppler sonography: measurement of changes in hepatic arterial haemodynamics following intra-arterial angiotensin II infusion. by Leen, E. et al.
Br. J. Cancer (1993), 67, 1381-1384 © Macmillan Press Ltd., 1993~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Duplex/colour Doppler sonography: measurement of changes in hepatic
arterial haemodynamics following intra-arterial angiotensin II infusion
E. Leen, W.J. Angerson, H.W. Warren, J.A. Goldberg, G.R. Sutherland, T.G. Cooke &
C.S McArdle
University Department ofSurgery, Royal Infirmary, Alexandra Parade, Glasgow G31 2ER, Scotland, UK.
Summary Angiotensin II (AT-IT) has been used to target regionally-administered cytotoxic microspheres in
patients with intrahepatic tumours. The optimisation of vasoconstrictor targeting requires a knowledge of the
blood flow changes induced by agents such as AT-IT. We therefore assessed duplex/colour Doppler sono-
graphy (DCDS) as a means of evaluating the effects of AT-TI infusion on hepatic arterial blood flow (HABF)
and arterial resistance in patients with intrahepatic tumours.
HABF was measured continuously in nine patients using DCDS before, during and after an infusion of
AT-II (15 micrograms in 3 ml of saline over 90 s) via a hepatic artery catheter. In seven patients with less than
30% hepatic replacement by tumour, the baseline level of HABF was 331 ± 85 ml min-' (mean ± s.d.), and
this was reduced by 75-80% within 30 s of the start of AT-II infusion. HABF recovered rapidly from the end
of the infusion, and increased by up to 20% above the baseline for approximately 2 min. In two patients with
greater than 50% hepatic replacement, HABF showed no reduction but rose continuously from the start of
AT-II infusion, increasing by a factor of 2-2.5 after 3-4 min. Arterial resistance showed reciprocal changes in
all cases.
We conclude that DCDS is effective in assessing the temporal changes in hepatic arterial blood flow caused
by AT-II. In order to optimise tumour targeting, the injection of microspheres loaded with cytotoxic drugs
should be completed before the end of the AT-II infusion. The targeting advantage of AT-lI in patients with a
high percentage hepatic replacement by tumour should be re-assessed.
The outlook for colorectal cancer patients with liver meta-
stases is poor. The median survival of those with multiple
metastases is approximately 6 months (Bengmark et al., 1969;
Wood et al., 1976; Wagner et al., 1984). Although recent
developments in surgical techniques have improved survival,
less than 5% of patients are likely to benefit from resection
of solitary metastatic deposits. Current regimes for systemic
chemotherapy are limited by high toxicity with lower drug
delivery to tumours. However regional chemotherapy pro-
duces more responses than systemic chemotherapy with
reduced toxicity, but significantly longer survival has not
been achieved yet. Methods of improving drug delivery selec-
tively to tumours to increase therapeutic effect without in-
creasing toxicity are therefore being investigated.
As established metastases receive their blood supply almost
exclusively from the hepatic artery, and since tumour vas-
culature is thought to be deficient in smooth muscle and
adrenergic innervation, the use of vasoactive agents may
increase tumour exposure to regional chemotherapy by alter-
ing the distribution of blood flow between tumour and nor-
mal liver. For example, intra-arterial infusion of angiotensin
II (AT-II) has been shown to enhance tumour uptake of
regionally-administered radiolabelled microspheres in patients
with colorectal liver metastases (Goldberg et al., 1991). Inves-
tigation of the blood flow changes induced by agents such as
AT-II is important for the optimisation of vasoconstrictor-
targeted chemotherapy and assessment of the targeting
advantage of individual patients. However, previously used
techniques for studying such effects are either invasive or of
restricted availability (Hemingway et al., 1992; Sasaki et al.,
1985). We therefore assessed duplex/colour Doppler sono-
graphy (DCDS) as a non-invasive means of investigating the
effects of vasoconstrictors in patients with liver tumours.
Methods
Nine patients (age range 48-69 years) with colorectal liver
metastases were studied. All patients had an indwelling
hepatic artery catheter with a subcutaneous injection port
(Portacath, Pharmacia, or Infusaid, Shiley Infusaid Inc.) for
administration of regional chemotherapy. The effects of an
angiotensin II infusion (given as 15 micrograms in 3 ml of
normal saline over 90 s on hepatic arterial blood flow
(HABF) were measured using DCDS (Diasonics Spectra,
Diansonics Sonotron Ltd, Bedford, UK) in conscious, fasted
patients. The technique for measuring HABF, which was
calculated as the product of the time average velocity and
arterial cross-sectional area, has been described previously
(Leen et al., 1991). The Diasonics Spectra scanner consists of
duplex and colour Doppler facilities and a 3.5 MHz convex
linear array probe was used. In the Doppler mode ultrasound
waves were emitted and received by a single probe at a
frequency of 3 MHz with a repitition frequency of 3.7 MHz.
A transverse scan was made at the epigastrium to locate
the common hepatic artery in its longitudinal axis. The Dop-
pler cursor was placed over the lumen of the artery segment
as near to the origin as possible, at the point where it first
became horizontally straight. Spectral analysis was performed
using fast Fourier transformation and the Doppler shift sig-
nal was displayed on the monitor. The system was equipped
with software to compute the time average velocity from the
spectral display automatically following placement of the
calipers at the start and end of four cardiac cycles. This was
done every 30 s while 15 micrograms of AT-II in 3 ml saline
was infused through the hepatic arterial catheter over a
period of 90 s.
The cross-sectional area of the artery was measured by
mapping the perimeter of the vessel lumen with the 'tracker
ball'. As it was not possible to do this simultaneously with
blood velocity measurement during the AT-II infusion, a
single value for the area was used to calculate flow rates for a
given patient. This was the mean of four individual
measurements taken at the same location in the vessel at
random phases of the cardiac cycle. In five patients, arterial
cross-sectional area was measured every 30 s during a
separate AT-II infusion. No systemic change in area was
observed during the infusion, and the mean coefficient of
variation of the area was only 3.9%, justifying the assump-
tion that it could be regarded as constant.
Mean arterial pressure was measured at 1 min intervals
during the AT-II infusion using an automatic sphygmo-
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manometer, and hepatic arterial resistance was calculated by
dividing mean arterial pressure by HABF. The hepatic
arterial resistive index (HARI) was also measured automatic-
ally from the velocity spectral display by the onboard soft-
ware using the formula HARI = (PSV-EDV)/PSV, where
PSV and EDV represent peak systolic velocity and end dias-
tolic velocity respectively.
The percentage hepatic replacement by metastases (PHR)
was measured using an IGE CT9800 Scanner from standard
dynamic enhanced examinations.
Informed consent was obtained from all patients. All data
were analysed using a Wilcoxson Signed Rank test.
distribution of hepatic arterial blood flow by causing tem-
porary arteriolar constriction in normal blood vessels while
having little direct effect on the immature tumour vascular
bed. In patients with low percentage hepatic replacement, the
response of hepatic arterial blood flow to AT-II would be
expected to reflect predominantly its effect on vessels supply-
ing normal liver tissue. This is in keeping with the immediate
rise in hepatic arterial resistance and fall in the hepatic
arterial blood flow observed in such patients in this study.
The vasoconstriction was rapidly reversed at the end of the
AT-II infusion, and was followed by a rise in the HABF
above the baseline - the 'rebound phase' - mirrored by a fall
Results
The mean HABF baseline level of all patients was
344mlmin-' (s.d.: 78) and this was significantly reduced to
about 180 ml min-' (trough phase) within 60 s of the AT-TI
injection (P<0.05). HABF then increased to a peak of
approximately 520 ml min-' between the third and fourth
minute after the start of AT-TI injection (rebound phase)
(Figure 1).
On analysis of the HABF changes in individual patients
and taking into account their PHR values, the following
observations were made:
In two patients, the PHR was over 55% (56% and 60%)
and in those patients there was no reduction in HABF
observed following the start of AT-TI infusion. HABF in-
creased instead by 2-2.5 times the baseline level over 3 to
4 min (Figure 1). The mean HARI fell from a baseline level
of 0.67 (s.d.: 0.02) to 0.55 (s.d.: 0.01) over 30 s and remained
at that level for approximately 5 min.
In seven patients, the PHR was less than 30% (median
29%, range 10-25%), the baseline level of HABF as
measured by DCDS was 331 ml min-' (s.d.: 85) and this was
reduced by 70-80% within 30s of the start of the AT-II
infusion. During the 'trough phase', HABF was significantly
reduced to a minimum of 72 ml min-' (s.d.: 34) (P<0.02),
and recovered rapidly from the end of the infusion. A post-
infusion 'rebound phase' was observed with a 20% increase
above baseline lasting for approximately 2 min (Figure 1).
In the same patients, mean arterial pressure rose from a
baseline of 95 mmHg (s.d.: 3.7) to a peak of 119 mmHg (s.d.:
16.9) over a period of 120-150 s from the start of the AT-II
infusion. The hepatic arterial resistance showed a biphasic
response which was approximately the inverse of the blood
flow changes (Figure 2). The HARI also showed a bisphasic
response, rising from a mean baseline level of0.67 (s.d.: 0.02)
to a peak of 0.83 (s.d.: 0.01) over a period of 60 s and then
decreased to below baseline to 0.64 (s.d.: 0.01) 210 s after the
start of AT-II infusion (Figure 2).
Discussion
Whilst the value of the qualitative information provided by
duplex/colour Doppler sonography is widely recognised,
there are still discussions as regards the accuracy of quan-
titative flow measurements. In previous studies using DCDS,
we have demonstrated the accuracy of this technique in vitro
and the reproducibility of HABF measurements in vivo (Leen
et al., 1991; Robertson et al., 1992). In the present study, our
primary interest was in relative changes in flow rather than
absolute values.
In seven of the nine patients, the trough phase was
observed. However, in the remaining two patients, no trough
phase was demonstrated and HABF increased from the start
of the AT-II infusion. The only factor that separated the two
groups was the PHR value; The group of patients in which a
trough phase was present, had a PHR value of less than 30%
whereas the group in which no trough phase was shown, had
a PHR over 50%. However this finding may conceivably be
due to chance.
Vasoactive agents such as AT-IT are believed to modify the
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ying this effect is un- outweighed by the reduction in flow to normal liver, may be
raemia, induced by the manifested in the later phase of the HABF response. npensating for a tem- The potent effectiveness of AT-II in targeting regionally-
iutrients. Alternatively administered chemotherapy to tumour is governed by the
nent of HABF supply- ratio of tumour to normal liver blood flow. The temporal
ig intra-operative laser changes in this ratio in patients with a low PHR may be
lood flow in hepatic inferred qualitatively from the results of the present study
)ns (Hemingway et al., and the tumour blood flow study discussed above. At the
gradually to a peak start of AT-II infusion the blood flow ratio would rise, ronisation with the in- primarily as a result of the fall in blood flow to normal liver,
; a result of pressure- and would continue rising while HABF remains in the
annels. This relatively 'trough phase' because of the continuing increase in tumour
low, although initially blood flow. The ratio would then begin to decline as normal
liver blood flow recovers at the end of the 'trough phase'
while the more slowly-changing tumour flow remains close to
its maximum. This pattern is consistent with the report of
Sasaki (1985) that the blood flow ratio during AT-II infusion
increased to a maximum at approximately 100 s, and then
slowing declined despite continued infusion of AT-II.
It is interesting to note that despite a 25% increase in the RH \ . .blood pressure, no significant change in the main hepatic
arterial cross-sectional area was demonstrated. We have
shown that these patients have significant enlargement of the
common hepatic artery compared with controls and it is
possible that a 25% increase in blood pressure would not
cause any further increase in the vessel diameter. However
some degree of vasoconstriction of the main hepatic arterial PHR <30% smooth muscle in response to AT-II that would counteract a
vasodilatation from the increase in blood pressure cannot be
5 * 4 * 5 excluded. 3 5 In contrast to patients with less than 30% hepatic replace-
ment, the two patients with over 55% hepatic replacement
showed no 'trough phase' following AT-II infusion. HABF
instead rose continuously to 2-2.5 times the baseline level
over 3-4 min. As there was more tumour bulk than normal
liver tissue, HABF would be expected to reflect mainly
- Mean HAR tumour blood flow. Although laser Doppler flowmetry failed to demonstrate a prolonged increase in blood flow in res-
ponse to AT-II in large tumour masses (Hemingway et al.,
1992), such an increase may have occurred outwith the
superficial measurement region accessible to the laser Dopp-
ler technique. However, the absence of even an attenuated
constrictor response in the present study is surprising as a
significant volume of apparently normal liver tissue was pre-
sent in these patients. It is possible that hepatic arteriolar
responsiveness to AT-II was impaired in the residual 'normal'
liver. The actual increase in hepatic arterial blood flow dur-
ing the infusion of AT-II may be due to the opening of
3 4 5 vascular channels of the tumour. Further studies are required
as PHR may be an important factor in determining AT-IT
targeting advantage.
Using hepatic scintigraphy, Goldberg and colleagues
(1991) showed that the use of AT-II (10 micrograms per min
given for 100 s) increased tumour uptake of regionally-
administered radiolabelled microspheres in patients with col-
orectal liver metastases. However, the microspheres were
injected after the end of the infusion of AT-TI, at which time
the present study suggests HABF would already be rising
-mean HARI towards the pre-angiotensin baseline. Depending on the time
taken to inject the microspheres, some of the targeting
advantage could therefore be lost. Ideally, cytotoxic micro-
spheres should be given as a bolus while HABF is still in the
trough phase, but this may not be possible for some prepara-
tions (for example polylactide microcapsules, which can take
up to 3-4 min to inject). To achieve optimum targeting in
. , . , these circumstances it may be necessary to prolong the AT-TI
4 5 infusion until the microsphere injection is complete.
In conclusion, DCDS is effective in assessing the temporal
changes in hepatic arterial blood flow caused by angiotensin
IT and will be useful in the evaluation of other vascoactive
;in II (AT II) infusion agents. In order to optimise tumour targeting, the injection
(mean ± s.d.), hepatic of microspheres loaded with cytotoxic drugs should be com-
I hepatic arterial resis- pleted before the end of the AT-II infusion. The targeting
ts with less than 30% advantage of AT-TI in patients with a high percentage
hepatic replacement by tumour should be re-assessed.
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